CGEM

Quote

Short

News

Articles

Message Board

Cullinan Therapeutics Inc. (NASDAQ : CGEM ) News

News Releases

CGEM News Releases

June 11, 2026 11:41:04 am

SeekingAlpha

Cullinan Therapeutics: Heading Toward Paydirt

June 10, 2026 05:32:10 pm

SeekingAlpha

Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcript

June 10, 2026 07:30:00 am

GlobeNewswire

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

June 06, 2026 05:15:00 am

GlobeNewswire

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

May 28, 2026 08:40:06 am

24/7 Market News

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks

May 26, 2026 07:00:00 am

GlobeNewswire

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

May 19, 2026 07:00:00 am

GlobeNewswire

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

May 18, 2026 05:00:00 pm

GlobeNewswire

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

May 18, 2026 08:34:00 am

Business Wire

The Biology Came First.

May 07, 2026 07:58:06 am

SeekingAlpha

Cullinan Therapeutics GAAP EPS of -$0.75

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account